Market Readiness for
a blockbuster launch
CASE STUDY
Blueprint of medical organization in context of overall business goals;
Unmet treatment need assessment;
Clinical study engagement framework.
Project 3 years in advance of launch.
Client
A small biotech company with an innovative technology platform for developing sustained-release formulations of existing medicines.
They already have one product in the market developed with their technology and are now moving forward with Phase III clinical testing of another compound targeting several different indications within a new therapy area.
Challenge
Small biotech companies often lack the manpower, cross-functional teams and organizational setup required to prepare for international launch success. A key challenge they often face is the need to ensure market readiness with a lean team and minimal resources until the late-stage clinical and regulatory studies are completed.
InnoStrat has the skills, network, and big pharma experience to support biotech companies at this critical juncture and we have a proven track record facilitating the transition from technological development to market execution at the local level.
In this case study, we were asked to provide input to the company’s medical strategy to support product launch in a new therapy area within a 3-year timeframe.
Solution
Four team leaders specializing in pharmaceutical value chain development/project management; commercial strategy; medical affairs strategy and market access and pricing.
Ad hoc, specialized team to support on organizational growth and HR resource planning, medical-operations excellence, plus design and implementation of Real World Evidence studies.
Our leadership role and ongoing collaboration in a regional biotech consortium gives us further access to a rich network of highly skilled biotech and pharma-trained individuals, as needed.
INNOSTRAT KEY DELIVERABLES AND TIMELINES
Blueprint of medical organisation in context of overall business goals
We conducted 1:1 Interviews with company leaders from R&D to medical affairs, marketing and market access to ensure a fully integrated and aligned medical strategy capable of supporting the target market positioning.
We helped define the structure of their Medical Science Liaison (MSL) set up, including identifying target MSL profiles for each launch country and facilitating the MSL teams in mapping and engaging key medical community leaders.
Unmet-needs assessment
As this was a new therapy area/indication for the company, we assessed the unmet treatment needs and established a Real-World Evidence (RWE) plan to complement their ongoing clinical study program in providing the necessary evidence base for successful market introduction (clinical acceptance, reimbursement, etc.)
Clinical-study engagement framework
Using our extensive experience in building sustainable study community engagement, we have built high-functioning and fully engaged clinical-trial teams at the local level.
Our patient-engagement partner helped secure the right patient profiles for the clinical studies to enhance both recruitment and retention and ensure on-time completion and credible data collection at local study sites.
FEEDBACK FROM OUR CLIENT